Dysregulation of the Hedgehog (Hh)-Gli signaling pathway is implicated in a variety of human cancers, including basal cell carcinoma (BCC), medulloblastoma (MB) and embryonal rhabdhomyosarcoma (eRMS), three principle tumors associated with human Gorlin syndrome. However, the cells of origin of these tumors, including eRMS, remain poorly understood. In this study, we explore the cell populations that give rise to Hh-related tumors by specifically activating Smoothened (Smo) in both Hhproducing and -responsive cell lineages in postnatal mice. Interestingly, we find that unlike BCC and MB, eRMS originates from the stem/progenitor populations that do not normally receive active Hh signaling. Furthermore, we find that the myogenic lineage in postnatal mice is largely Hh quiescent and that Pax7-expressing muscle satellite cells are not able to give rise to eRMS upon Smo or Gli1/2 overactivation in vivo, suggesting that Hh-induced skeletal muscle eRMS arises from Hh/Gli quiescent non-myogenic cells. In addition, using the Gli1 null allele and a Gli3 repressor allele, we reveal a specific genetic requirement for Gli proteins in Hh-induced eRMS formation and provide molecular evidence for the involvement of Sox4/11 in eRMS cell survival and differentiation.
INTRODUCTION
The mammalian Hedgehog (Hh) signaling pathway is involved in a variety of developmental and tumorigenic processes through regulation of cell proliferation, survival and differentiation. [1] [2] [3] In mammals, Hh ligands bind to the receptor, Patched1 (Ptch1), resulting in relieving inhibition of a 7-transmembrane protein, Smoothened (Smo). Activated Smo signals through an intracellular pathway to control the activities of the Gli family transcription factors, including Gli1, Gli2 and Gli3, which collectively regulate the transcription of downstream target genes. 1, [4] [5] [6] [7] The first evidence linking Hh pathway activity to human cancer was the identification of germline mutations of Ptch1 in Gorlin syndrome, an autosomal disease associated with an increased incidence of basal cell carcinoma (BCC), medulloblastoma (MB) and rhabdomyosarcoma (RMS). [8] [9] [10] Studies using genetically modified mouse models also established a clear link between abnormal Hh activity and development of these tumor types. [11] [12] [13] [14] [15] [16] [17] [18] MB is the most common childhood brain tumor, and Hh-related MB is likely derived from the committed cerebellar granule neuron precursors. [18] [19] [20] [21] [22] BCC is believed to arise from the skin epidermis, although it is still under debate whether it is derived from the interfollicular epidermis or from hair follicle stem cells. [23] [24] [25] [26] Hh/Gli dysregulation is also associated with the genesis of embryonal RMS (eRMS), the major subtype of the most common soft tissue sarcoma in children. [27] [28] [29] [30] Amplification or losses of the chromosomal regions containing genes for Hh pathway components, including Gli1, Ptch1 and Sufu, in a significant portion of human eRMS. [31] [32] [33] [34] Furthermore, Hh pathway activation has been shown in the majority of sporadic eRMS cases and confers a poor prognosis in patients with these tumors. 34, 35 However, the exact cellular origin of eRMS and how Hh/Gli dysregulation contributes to eRMS formation remains poorly characterized.
Our previous study established a robust mouse model that mimics Hh-induced sporadic tumorigenesis through postnatal inducible Smo activation. 17 This model provides a genetic platform to study Hh-related eRMS with 100% penetrance. However, the ubiquitous nature of the CAGGS CreER line used in that study prevents further analysis of tumor cellular origins. Thus, in the current study we specifically activated Smo in postnatal Hh-expressing or -responsive lineages and showed that BCC and MB could be generated from the Hh-responsive progenitor cells within the hair follicle and developing cerebellum. However, we found that eRMS did not arise from either Hh-expressing or Hh-responsive populations. Genetic analysis of postnatal myogenic lineages revealed that the Hh pathway was not active in postnatal myogenesis. Using the recently established Rosa26 Gli1 and Gli2 conditional alleles, we further showed that neither Smo nor Gli1/2 activation in postnatal Pax7 þ muscle stem cells was sufficient to drive eRMS formation, arguing for a cell of origin in Hh/Gli-quiescent non-myogenic stem/progenitor populations. Moreover, we presented evidence for downstream involvement of Gli1-independent and Sox4/11-dependent maintenance of cell survival and transformation of Hh-induced eRMS cells. 14 Following a single dose of tamoxifen injection at postnatal day 10 (P10), 40% of the CAGGS CreER ;R26 SmoM2 mice developed medulloblastoma, and all of the mice displayed BCC and eRMS within 4 months (Figure 1a) .
RESULTS

Constitutive
To further characterize the originating cell populations for these tumors, we used two inducible Cre alleles, Shh CreER , 37 and Gli1
CreER . 38 Shh CreER has a tamoxifen-inducible Cre recombinase (CreER T2 ) targeted into the Shh locus under the control of the endogenous Shh promoter. 37 We first generated Shh CreER ;R26 Figure 1a ). Consistent with previous reports that MB and BCC are probably not derived from Shh-expressing progenitors, 18, 23 our results suggest that eRMS also arises from a Shh-independent lineage, and that autocrine Hh regulation is not likely involved in initiation of these Gorlin tumors.
The inducible Gli1 CreER allele contains CreER T2 targeted into the endogenous Gli1 locus. 38 Recent studies have established that Hh activity is both necessary and sufficient for Gli1 transcription, and that Gli1 expression provides a faithful and sensitive readout of the Hh signaling activity. 38 Figure 1a ). These unique tumor spectra suggest that, unlike BCC and MB, eRMS does not originate from Hh-responsive cells, but rather from cell populations that are not normally undergoing active Hh signaling.
SmoM2 activation in Gli1-expressing cerebellar and hair follicle progenitor cells To further characterize Hh-responsive populations in postnatal mice, we crossed Gli1
CreER to the Rosa26 reporter strain, R26R.
43
We examined Gli1-expressing cells at postnatal day 12 (P12) after tamoxifen injection at P10. Consistent with previous reports, [18] [19] [20] [21] we found that Gli1 was highly expressed in the cerebellar granule neuron precursors in the developing cerebellum ( Figure 1b) . We also detected a precursor lesion in all Gli1 CreER ;R26 SmoM2 mice (n ¼ 9) examined at postnatal day 30 (P30). These lesions were often located at the surface of the cerebellum and were highly proliferative ( Figure 1c and Supplementary Figure 1A ) similar to the pre-neoplastic lesions described in Ptch1 þ / À mice. 21 Subsequently, a portion of these lesions gave rise to MB (Figure 1d ). Furthermore, we found that SmoM2 activation in Gli1 þ postnatal neural stem cell populations in the forebrain did Figure 1B) , supporting the idea that Hh-induced MB arise from cerebellar granule neuron precursors. 18 In the postnatal skin, Gli1-expressing cells were detected within the hair follicle, and we found no evidence of a Gli1-expressing lineage in the normal interfollicular epidermal epithelium (Figure 1e) Following tamoxifen injection at P10, we analyzed the skeletal muscle of the Gli1
CreER ;R26R mice at P12 and P90. We did not detect any b-galactosidase-positive myofibers at either time point (Figure 2a ). Although the majority of the muscle cells are Hh pathway-negative, we did notice that a very small subset of cells located among the muscle fibers were positively labeled ( Figure 2a ). To further characterize these cells derived from the Hh-responsive lineage, we performed immunostaining of laminin and b-galactosidase. Interestingly, these b-galactosidase-positive cells were exclusively located in the interstitial regions outside the basal lamina (Figures 2b-d) . It suggests that they are unlikely to be muscle satellite cells, the postnatal myogenic stem cell population responsible for muscle cell growth and differentiation, as satellite cells and their descendent myoprogenitors are normally located underneath the basal lamina. Further analysis showed that these b-galactosidase-positive cells were largely Sca1 þ (Figures 2e-g ), suggesting the association with the hematopoietic, rather than the myogenic lineage. Together, our analyses suggest that Hh pathway is largely quiescent in myogenic stem/progenitor cells during normal postnatal myogenesis, although it remains to be determined whether the Hh-Gli pathway is activated within the myogenic lineage during injury-induced muscle regeneration. However, our Gli1
CreER ;R26 SmoM2 results clearly indicate that these normal Gli1 þ cells are not the origin of Hh-related eRMS ( Figure 1a ).
Hh activation in juvenile muscle stem/progenitors in vitro To further examine Hh signaling activity in postnatal muscle stem/ progenitor cells, we isolated primary myogenic cells from the wildtype mouse hind limb muscle at P10, a time point that has been used in our tamoxifen-induced tumor models ( Figure 1 to induce SmoM2 expression (Figure 3b ). Significant upregulation of the Hh target genes, Ptch1, Gli1 and Hip1, was detected after 4-hydroxy-tamoxifen treatment (Figure 3c ), indicating Hh pathway activation. However, we found that ectopic expression of SmoM2 did not promote proliferation of these primary cells, as measured by MTT-based assay and Ki67 staining (Figure 3d and data not shown, respectively). Primary myogenic progenitors undergo apoptosis under differentiation conditions. 47, 48 Interestingly, SmoM2 activation partially protected the cells from apoptosis when switching to the differentiation media or after exposure to apoptotic stimulus cycloheximide. SmoM2 expression led to lower caspase-3/7 activity in primary cells with tamoxifen treatment after serum deprivation or cycloheximide treatment (Figure 3e and Supplementary Figure 2A) . Next, we examined whether myogenic differentiation of these progenitor cells can be regulated by Hh pathway overactivation. We found that SmoM2 impaired cell differentiation, as assessed by the expression of the skeletal muscle myosin heavy chain (MyHC) in primary cells grown in differentiation media for 6 days (Figure 3f and Supplementary Figures 2B-D) . Collectively, these data suggested that juvenile myogenic progenitor cells are normally Hh signaling-quiescent, but are capable of responding to Hh upregulation, and that cell-autonomous SmoM2 activation promotes cell survival and differentiation in vitro.
SmoM2 and Gli1/2 activation in postnatal muscle satellite cells in vivo To examine the in vovo effect of Hh/Gli on postnatal muscle stem cells, we crossed the inducible satellite cell Cre driver, Pax7
CreER , 49 to R26 SmoM2 , R26 Gli1 , 50 and R26 Gli2DN mice. R26 Gli2DN is a Rosa26 conditional knockin allele of Gli2 recently generated in the lab that enables Cre-dependent expression of a constitutively active N-terminally truncated form of Gli2 fused with a N-terminal 3XFlag tag (Figure 3g ). These genetic approaches allow us to achieve pathway activation at both the cell surface Smo level and downstream Gli level because Hh ligand/receptor-independent Gli1/2 regulation is also involved in tumorigenesis. 6, 7, 10 
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Hedgehog (Figure 3i ), suggesting that Hh/Gli activation in vivo in postnatal satellite cells is not sufficient to drive eRMS formation. More importantly, it suggests that eRMSs developed in the skeletal muscle of the CAGGS CreER ;R26 SmoM2 mice may arise from a Hh/Gli-quiescent non-myogenic cellular origin.
Genetic requirement of Gli proteins in Hh-induced RMS Among the three mammalian Gli proteins, Gli1 and Gli2 mainly function as transcriptional activator, while Gli3 largely acts as a transcriptional repressor. 6, 7 Gli1 itself, a transcriptional target of Hh signaling, is dispensable for normal development but likely involved in tumorigenesis. 6, 7 A previous report showed that removing Gli1 activity in the Ptch1 þ / À MB model is able to partially block tumor formation. 51 Our transcriptional profiling and expression analysis showed that both Gli1 and Gli2 are upregulated in SmoM2-induced eRMS ( 17 and Figure 4a ), indicating a broad involvement of Gli activity in eRMS. However, the genetic requirement of Gli proteins in eRMS formation has not been examined.
To address this question, we utilized the Gli1 null allele 40 and a Gli3 transcriptional repressor allele, R26
Gli3T
. 52 Gli3T lacks the C-terminal transcriptional activation domain and functions as a constitutive transcriptional repressor, 53 and was able to effectively inhibit SmoM2-, Gli1-, and Gli2-induced transcriptional activity, as determined by a Gli-luciferase reporter assay (Figure 4b ). We generated CAGGS CreER ;R26
SmoM2
;Gli1
-/-and CAGGS CreER ; R26 SmoM2 ;R26 Gli3T mice and monitored eRMS formation following tamoxifen injection at P10. We found that removing Gli1 activity did not significantly affect SmoM2-induced eRMS formation, as measured by tumor incidence, size and proliferation status (Figures 4c-e) . However, we found that inhibition of Gli-mediated transcription by Gli3T was able to block Hh-induced tumorigenesis, including eRMS ( Figure 4C) (Figure 4c ). Histology analysis of the skeletal muscle of CAGGS CreER ;R26 SmoM2 ;R26 Gli3T mice also did not reveal early hyperproliferative eRMS lesions (data not shown). These data demonstrate the genetic requirement of Gli activation in eRMS in vivo, but suggest that Gli1 is largely dispensable for SmoM2-induced eRMS formation.
To further examine Gli activity in eRMS cells, primary tumor cells isolated from the hind limb eRMS of the CAGGS CreER ;R26 SmoM2 mice were infected with lentivirus expressing Gli3T or shRNAs against Gli1 (shGli1) or Gli2 (shGli2) or treated with GANT61, a small molecule Gli inhibitor that is capable of inhibiting both Gli1-and Gli2-mediated transcription. 54 Consistent with the in vivo tumorigenesis analysis, we found that shGli1 expression did not inhibit Hh pathway activation, tumor cell proliferation and survival. Further, it did not significantly synergize the inhibitory effect of Gli2 knockdown (shGli2) (Figures 4f-h ). In contrast, Gli3T expression or GANT61 treatment effectively blocked tumor cell proliferation and survival (Figures 4f-h) . Altogether, it suggested that Gli2, but not Gli1, is likely the major Gli mediator in these primary eRMS tumor cells.
Sox4/11 involvement in Hh-dependent eRMS
The downstream molecular mechanism underlying Hh-Gli dysregulation in eRMS remains poorly understood. The SoxC transcription factors have been reported to play important roles in tumorigenesis in several cancer types, [55] [56] [57] [58] although it is not clear whether these factors are involved in eRMS. Interestingly, our previous gene expression profiling studies in CAGGS CreER ;R26
SmoM2
mice showed that Sox4 and Sox11, two closely related SoxC factors, were highly upregulated in SmoM2-induced eRMS, 17 which prompted us to examine whether Sox4/11 have an oncogenic role in Hh-dependent eRMS cells. Consistent with the expression profiling data, we found that Sox4 and Sox11 were highly expressed in SmoM2-induced eRMS cells, compared to the wild-type skeletal muscle, as measured by immunoblot and q-PCR analyses (Figures 5a and b) . Furthermore, lentiviral expression of Gli3T in these primary eRMS cells resulted in downregulation of Sox4 and Sox11 expression (Figures 5c and d) , suggesting that Sox4/11 may act downstream of Hh signaling in eRMS. To explore their potential functional roles, we generated shRNAs against mouse Sox4 and Sox11. Knockdown of either Sox4 or Sox11 alone in these cultured eRMS cells had little or no effect (Figures 5f and g ), suggesting a possible functional redundancy between these two factors. However, the presence of shRNAs against both Sox4 and Sox11 was able to inhibit Sox4/11-induced transcription activation (Figure 5e ), blocked proliferation (Figure 5f ) and induced apoptosis (Figure 5g ) in the primary eRMS cells. Interestingly, we found that Sox4/11 knockdown also disrupted the differentiation program of eRMS cells. q-PCR analysis showed that expression of the myogenic markers, including Pax7, Myf5 and MyoD, was downregulated after Sox4/11 knockdown (Figure 5h) . Together, these data suggest that Sox4/11 proteins may play an important role downstream of Hh/Gli in regulation of eRMS cell proliferation, survival and differentiation. DISCUSSION BCC, MB and eRMS are three original tumors associated with the Gorlin syndrome and Hh pathway dysregulation. Our data here support the model that Shh-related MB originates from Gli1-expressing cerebellar granule neuron precursors. 18 The exact origin of BCC is still under debate. A recent study suggests that the hair follicle stem cell niche resists transformation by the Hh pathway, 23, 24 while other studies using different transgenic models show that follicle stem cells can give rise to BCC. 25, 26, 59 Interestingly, a recent report shows that Gli1 is expressed in a distinct subpopulation of hair follicle bulge stem cells. 42 Our study using the Gli1
CerER allele indicates that the Gli1 þ follicular stem/progenitor cells are capable of generating BCC upon Smo activation.
eRMS is an aggressive muscle tumor, and its cellular origin remains elusive. 30 It was generally thought that eRMS arises from cells of the myogenic lineage, largely due to the expression of early or late myogenic markers, such as Pax7, MyoD and Myogenin. Indeed, recent studies showed that postnatal Pax7 þ satellite cells or myogenic progenitor populations can give rise to RMS, including eRMS, upon deletion of the tumor suppressor p53 or activation of oncogenic Kras. 45, 46 However, eRMS-initiating populations are likely heterogeneous. The drastic difference of eRMS incidence in our CAGGS CreER ;R26 SmoM2 and Gli1 CreER ;R26
SmoM2 models provides an interesting clue to the cellular origin of Hhinduced eRMS. It suggests that, unlike BCC and MB, the other two tumors associated with Gorlin syndrome, eRMS is instead derived from Hh/Gli-quiescent stem/progenitor cells. Our genetic fatemapping experiments suggest that Hh signaling is quiescent during postnatal myogenesis, and muscle satellite cells do not normally carry active Hh signaling, although they retain the capacity to respond to Hh overactivation. Further, our data demonstrated that neither SmoM2 expression nor downstream Gli1/2 activation in Pax7 þ postnatal satellite cells is able to drive eRMS formation in vivo. Collectively, these experiments argue that Hh-induced postnatal eRMSs arise from Hh/Gli-quiescent nonmyogenic populations. Our data are consistent with a recent report that SmoM2 expression from the adipocyte progenitors can give rise to a subset of eRMS. 60 Interestingly, in this aP2
Cre ;R26 SmoM2 model, eRMS is only detected in the head and neck region, 60 while in our CAGGS CreER ;R26 SmoM2 model, eRMSs are predominantly located in the limbs and trunk region, 17 pointing to a distinct, yet unidentified cell of origin for these eRMS.
The involvement of Hh/Gli signaling in eRMS development is multifaceted. It is likely that Hh overactivation in the nonmyogenic progenitors, including those of the adipose lineage, 60 may drive transdifferentiation into eRMS. Intriguingly, we found that, although Hh/Gli activation in juvenile satellite cells alone is not sufficient to induce eRMS in vivo, it can regulate the survival and differentiation of primary juvenile satellite cells in culture. We did not detect significant stimulation of cell proliferation by Hh, in contrast to a previous report for such effect on cultured adult satellite cells. 61 It is probably due to distinct characteristics between juvenile and adult satellite cells. 49 However, these results support the idea that Hh pathway may function as an oncogenic modifier in RMS arising from the myogenic lineage. 46 It was recently reported that heterogeneous deletion of Ptch1 in the p53 RMS mouse model shifts the tumor spectrum towards the eRMS type. 46 In addition to tumor initiation, Hh activity is also important for eRMS progress. Hh pathway activation is detected in the majority of sporadic eRMS cases. 34, 62 Our genetic study here demonstrated the in vivo requirement for Gli-mediated transcription in eRMS. However, it appears that Gli1 may not be critical for SmoM2-induced eRMS development, although Gli1 has been reported to have roles in other Hh-related tumorigenic settings. 6, 7, 51 Our results suggested a novel oncogenic role for the Sox4/11 factors in eRMS. SoxC transcription factors are essential for embryonic mesenchymal progenitor survival. 63 Sox4 or Sox11 upregulation has also been implicated in hematopoietic and nonhematopoietic malignancies. [55] [56] [57] [58] 64 Our data are the first to link the SoxC factors to eRMS. We showed here that the activities of Sox4 and Sox11 are critical for tumor cell proliferation and survival, and that these factors may also play a role in eRMS cell differentiation. It is worth noting that Hh signaling itself also regulates eRMS cell differentiation through direct interaction between Gli proteins and the myogenic transcription factor MyoD. 65 Clearly, further elucidation of the functional interplays among these critical pathways may lead to future design of more effective strategies for diagnosis and treatment of eRMS.
MATERIALS AND METHODS
Mouse strains
CAGGS
CreER , Gli1
CreER , Shh
CreER , Pax7
CreER , R26R, R26
SmoM2
, R26 Gli1 and R26 Gli3T mice have been described before. 17, [36] [37] [38] 43, 49, 50, 52 To generate the R26 Gli2DN allele, the cDNA encoding the N-terminally truncated activated form of Gli2 fused with a N-terminal 3X Flag tag was inserted into the shuttling vector pBigNeoT before being cloned in pROSA-PAS to produce the final targeting construct for ES cell targeting. Mice used in this study were in a mixed genetic background, including 129/Sv and Swiss Webster as main components, and all mouse experiments were performed according to the guidelines of IACUC at University of Massachusetts Medical School.
Tamoxifen treatment, tissue collection and histology Primary myogenic progenitor and eRMS cell isolation and culture Isolation of primary myogenic progenitor cells from mouse hind limb skeletal muscles at P10 was performed using a two-step protocol, including isolation of single muscle fibers, followed by releasing myoprogenitor cells from isolated fibers. Briefly, the hind limb muscle was digested in 0.2% collagenase and incubated in a shaking water bath at 371C for 90 min. Heat-polished glass Pasteur pipetters were then used to triturate and dissociate muscle into single fibers. After washing, a collagenase/dispase solution was used to purify myogenic progenitor cells from the fibers. The isolated cells were cultured in the growth media containing 20% FCS and 5 ng/ml bFGF. To activate Hh/Smo signaling, fiberassociated myogenic cells isolated from the mice carrying the R26-SmoM2 alleles were treated with 1mg/ml 4OH-tamoxifen for 2 days. To isolate eRMS tumor cells, the hind limb eRMS tumors from CAGGS CreER ;R26 SmoM2 mice were dissected, minced and digested in 0.5% Trypsin and 0.2% collagenase at 37 1C with agitation. After 20 min, the digested material was filtered through a 105-mm nylon mesh and freshly isolated eRMS cells were then cultured in DMEM supplemented with 10% FBS and subjected to further analysis.
Cell proliferation, apoptosis and differentiation assays
For MTT-based cell proliferation assay, cells were seeded at a density of 6000 per well in a 96-well plate. After 5 mg/ml MTT treatment at 2, 4 and 6 days after seeding, cells were lysed in DMSO and absorbance was measured at 595 nm. For myogenic progenitor differentiation assay, the culture media was replaced with the differentiation media that contained 5% horse serum. The cells were harvested at day 0 (immediately before switching to the differentiation medium) and day 6 for western blotting or immunoflorescence analyses of MyHC expression. Apoptosis and caspase-3/7 activity was determined using the Caspase-Glo 3/7 assay system (Promega, Madison, WI, USA) in accordance with the manufacturer's instructions.
Quantitative Luciferase reporter analysis NIH3T3 cells were transfected with the luciferase reporter constructs, Sx6X-Luc (gift of Dr Michael Wegner, Universitat Erlangen-Nurnberg), GliBS-Luc (gift of Dr H Kondoh, Osaka University) and the expression vectors for Renila luciferase, SmoM2, Gli1, Gli2DN, Gli3T, Sox4 and Sox11. Luciferase assays were conducted 48 h after transfection using the dual-luciferase reporter kit (Promega).
